Suppr超能文献

抗抑郁药物与 2 型糖尿病和糖调节受损风险:系统评价。

Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review.

机构信息

Corresponding author: Katharine Barnard,

出版信息

Diabetes Care. 2013 Oct;36(10):3337-45. doi: 10.2337/dc13-0560.

Abstract

OBJECTIVE

Antidepressant use has risen sharply over recent years. Recent concerns that antidepressants may adversely affect glucose metabolism require investigation. Our aim was to assess the risk of type 2 diabetes associated with antidepressants through a systematic review.

RESEARCH DESIGN AND METHODS

Data sources were MEDLINE, Embase, PsycINFO, The Cochrane Library, Web of Science, meeting abstracts of the European Association for the Study of Diabetes, American Diabetes Association, and Diabetes UK, Current Controlled Trials, ClinicalTrials.gov, U.K. Clinical Research Network, scrutiny of bibliographies of retrieved articles, and contact with relevant experts. Relevant studies of antidepressant effects were included. Key outcomes were diabetes incidence and change in blood glucose (fasting and random).

RESULTS

Three systemic reviews and 22 studies met the inclusion criteria. Research designs included 1 case series and 21 observational studies comprising 4 cross-sectional, 5 case-control, and 12 cohort studies. There was evidence that antidepressant use is associated with type 2 diabetes. Causality is not established, but rather, the picture is confused, with some antidepressants linked to worsening glucose control, particularly with higher doses and longer duration, others linked with improved control, and yet more with mixed results. The more recent, larger studies, however, suggest a modest effect. Study quality was variable.

CONCLUSIONS

Although evidence exists that antidepressant use may be an independent risk factor for type 2 diabetes, long-term prospective studies of the effects of individual antidepressants rather than class effects are required. Heightened alertness to potential risks is necessary until these are complete.

摘要

目的

近年来,抗抑郁药的使用急剧增加。最近有担忧称,抗抑郁药可能会对葡萄糖代谢产生不良影响,需要对此进行调查。我们的目的是通过系统评价评估抗抑郁药与 2 型糖尿病风险之间的关联。

研究设计和方法

数据来源包括 MEDLINE、Embase、PsycINFO、The Cochrane Library、Web of Science、欧洲糖尿病研究协会、美国糖尿病协会和英国糖尿病协会会议摘要、当前对照试验、ClinicalTrials.gov、英国临床研究网络、检索文章的参考文献审查以及与相关专家的联系。纳入了评估抗抑郁药作用的相关研究。主要结局是糖尿病发病率和血糖变化(空腹和随机)。

结果

有 3 项系统评价和 22 项研究符合纳入标准。研究设计包括 1 项病例系列和 21 项观察性研究,包括 4 项横断面研究、5 项病例对照研究和 12 项队列研究。有证据表明抗抑郁药的使用与 2 型糖尿病有关。虽然尚未确定因果关系,但情况较为复杂,一些抗抑郁药与血糖控制恶化有关,特别是在高剂量和长时间使用时,而其他抗抑郁药与控制改善有关,还有一些则结果不一。然而,最近的、更大规模的研究表明,这种影响较为适度。研究质量存在差异。

结论

尽管有证据表明抗抑郁药的使用可能是 2 型糖尿病的一个独立危险因素,但需要进行长期前瞻性研究,以评估个体抗抑郁药而非药物类别的作用。在这些研究完成之前,有必要对潜在风险保持高度警惕。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a96c/3781547/d38fd9a9d371/3337fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验